Erasca, Inc.
ERASNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ERAS. That does not mean none is planned.
Get an email about ERAS's next catalysts
Track Erasca (ERAS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming, 1 past
ERAS Reports Financial Results
Filed: 2026-11-12 AccNo: 0001193125-26-458350 Size: 346 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
SourceMarket Overview
Stock performance and key metrics
Naporafenib
Advanced or Metastatic NRAS-mutant Melanoma
Encorafenib
Metastatic Colorectal Cancer
ERAS-007
Advanced or Metastatic Solid Tumors
ERAS-601
Advanced or Metastatic Solid Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Naporafenib | Phase 3 | Advanced or Metastatic NRAS-mutant Melanoma | - | - |
Encorafenib | Phase 2 | Metastatic Colorectal Cancer | - | - |
ERAS-007 | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
ERAS-601 | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
Metastatic Colorectal Cancer
1 drug in this indication
Advanced or Metastatic NRAS-mutant Melanoma
1 drug in this indication
Advanced or Metastatic Solid Tumors
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Erasca, Inc.'s drug pipeline?β
CatalystAlert tracks 4 drug candidates in Erasca, Inc.'s (ERAS) pipeline across Phase 3, Phase 2. Its lead program is Naporafenib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Erasca, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Erasca, Inc. (ERAS) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track ERAS biotech catalysts?β
Add ERAS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Erasca, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
